Abstract:Background: Accumulating evidence indicates that metabolic events profoundly modulate the progression of various diseases. The pyruvate kinases catalyze the production of pyruvate and pyruvate kinase M2 (PKM2) is a unique isoform involved in the development of tumors. In the present study, the pathological significance of PKM2 has been investigated in mice with lipopolysaccharide/D-galactosamine (LPS/D-Gal)-induced fulminant liver injury. Methods: Fulminant liver injury was induced in mice by intraperitoneal injection of LPS/D-Gal, the level of nuclear PKM2, the activity of pyruvate kinase and the content of pyruvate were determined. To investigated the significance of PKM2/ pyruvate, the PKM2 modulator TEPP-46, DASA-58 or the cell permeable ethyl pyruvate (EP) was administered and the degree of hepatocyte apoptosis and liver damage were evaluated. In addition, phospho-antibody microarray was used to identify the underlying signaling pathways. Findings: LPS/D-Gal exposure increased the nuclear level of PKM2 but decreased the activity of pyruvate kinase and the content of pyruvate. Treatment with the PKM2 modulator TEPP-46 or supplementation with ethyl pyruvate (EP) suppressed LPS/D-Gal-induced liver damage. Interestingly, post-insult administration of TEPP-46, another PKM2 modulator DASA-58 or EP also resulted in beneficial outcomes. The phospho-antibody microarray analysis found that LPS/D-Gal induced inhibitory phosphorylation of cyclin dependent kinase 1 (CDK1), which was reversed by TEPP-46, DASA-58 or EP. In addition, the therapeutic benefits of TEPP-46 or EP were blunted by the CDK1 inhibitor Ro 3306. Interpretation: Our data suggests that LPS/D-Gal exposure-induced accumulation of nuclear PKM2, decline of pyruvate and inactivation of CDK1 might be a novel metabolic mechanism underlies the development of LPS/D-Gal-induced fulminant liver injury, PKM2/pyruvate might be a promising target for the pharmacological intervention of fulminant hepatocyte damage. Funding: This work was supported by the grants from the National Natural Science Foundation of China (No. 81871606) and the grant from Science and Technology Research Program of Chongqing Municipal Education Commission (No. KJQN201900435). Declaration of Interest: None to declare. Ethical Approval: The Ethics Committee of Chongqing Medical University approved all mouse experiments.

Nuclear Accumulation of Pyruvate Kinase M2 Promotes Liver Regeneration Via Activation of Signal Transducer and Activator of Transcription 3.

Accumulation of Nuclear PKM2 Promotes LPS/D-Gal-Induced Fulminant Liver Injury via Reduction of Pyruvate and Inactivation of CDK1

Pyruvate Kinase M2 Tetramerization Protects Against Hepatic Stellate Cell Activation and Liver Fibrosis.

Activation of PKM2 Metabolically Controls Fulminant Liver Injury Via Restoration of Pyruvate and Reactivation of CDK1.

Nuclear PKM2 Regulates Β-Catenin Transactivation Upon EGFR Activation.

PKM2 Promotes Metastasis by Recruiting Myeloid-Derived Suppressor Cells and Indicates Poor Prognosis for Hepatocellular Carcinoma.

Nuclear PKM2 Regulates the Warburg Effect.

Pyruvate Kinase M2 Regulates Fibrosis Development And Progression By Controlling Glycine Auxotrophy In Myofibroblasts

PKM2 Is Essential for Bladder Cancer Growth and Maintenance

Phosphatidic acid-enabled MKL1 contributes to liver regeneration: translational implication in liver failure

Role of Pyruvate Kinase M2 and Its Potential Pathogenic Mechanisms in Human Hepatocellular Carcinoma

Pyruvate Kinase Type M2 is Upregulated in Colorectal Cancer and Promotes Proliferation and Migration of Colon Cancer Cells.

PKM2: A Potential Regulator of Cardiac Injury Through Glycolytic and Non-glycolytic Pathways

Pyruvate Kinase M2 Phosphorylates H2AX and Promotes Genomic Instability in Human Tumor Cells.

A Novel Role for Pyruvate Kinase M2 As a Corepressor for P53 During the DNA Damage Response in Human Tumor Cells*

Pyruvate kinase M2 interacts with nuclear sterol regulatory element–binding protein 1a and thereby activates lipogenesis and cell proliferation in hepatocellular carcinoma

HDAC8-dependent Deacetylation of PKM2 Directs Nuclear Localization and Glycolysis to Promote Proliferation in Hepatocellular Carcinoma.

Pyruvate kinase M2 regulates kidney fibrosis through pericyte glycolysis during the progression from acute kidney injury to chronic kidney disease

Pyruvate Kinase M2 Mediates Fibroblast Proliferation to Promote Tubular Epithelial Cell Survival in Acute Kidney Injury.

Mitogenic and Oncogenic Stimulation of K433 Acetylation Promotes PKM2 Protein Kinase Activity and Nuclear Localization

Pyruvate Kinase M2 is Highly Expressed in Cutaneous Squamous Cell Carcinoma and Promotes Its Progression